Advertisement

Topics

Cancer Therapies Using Engineered Monomeric Fc Molecules

09:07 EDT 13 Sep 2018 | NIH

The National Cancer Institute, Nanobiology Program seeks parties interested in collaborative research to co-develop engineered molecules therapies.

Efforts to engineer antibody-based therapeutics, to date, have encountered technical limitations due to the relatively large fragment size and short fragment half-life. Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small size and other unique properties. However, compared with full-size antibodies, these antibody fragments lack the ability to bind to some Fc receptor and have reduced half-lives.

NCI scientists have developed small (∼27 kDa) antibody fragments that are potentially useful for therapeutic development.  These are monomeric IgG fragment (mFc) compositions; they have long half-lives, are functional (pH dependent binders of neonatal Fc receptor - FcRn); soluble, and they express in E. coli efficiently.  The molecules may serve as a platform for development of engineered mFc-based antibodies and fusion proteins with therapeutic applications: the smaller size may allow for superior access to targets and tissues compared to full sized mAbs and larger fragment-based therapeutics, while also retaining important functional characteristics. The IgG Fc is a dimer of two constant domains (CH2-CH3 chains). The Fc has a long half-life, which makes it promising as a candidate for engineering antibody therapeutics.  

IC: 
NCI
NIH Ref. No.: 
E-019-2012
Advantages: 
  • Smaller size results in reduced steric hindrance
  • Increased therapeutic efficiency
Applications: 

Therapeutics - human and veterinary, engineered antibody and fusion proteins.

Development Status: 

Discovery (Lead Identification)

Updated On: 
Jul 19, 2018
Provider Classifications: 
Publications: 
Patent Application: 
61/063,245
12/864,758
Patent Authority: 
U.S.
U.S.
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
NCI
Inventor Lab URL: 
https://ccr.cancer.gov/Cancer-and-Inflammation-Program/dimiter-s-dimitrov
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Therapeutics
DTDT Description: 
Therapeutics
Pat Filing Date: 
2008-01-31
2010-01-07
Publication Link: 
https://www.ncbi.nlm.nih.gov/pubmed/16101424
Publication Caption: 
PMID 22518843
Publication Title: 

Ying T, et al.  Soluble monomeric IgG1 Fc. 

Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Licensing only

E Number Only: 
E-019-2012
Inventor First Name: 
Dimiter
Tianlei
Inventor Last Name: 
Dimitrov
Ying

Original Article: Cancer Therapies Using Engineered Monomeric Fc Molecules

NEXT ARTICLE

More From BioPortfolio on "Cancer Therapies Using Engineered Monomeric Fc Molecules"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...